Request Trial
JarTee / Shutterstock.com
15 May 2025NewsPharmaMarisa Woutersen
|

Novartis tops Big Pharma in global trademark portfolios

Trademark activity surged across major markets in 2024 | Swiss pharma ranks among top foreign portfolios in US, UK and EU | Mainland China is largest filer worldwide despite dip in applications | Several major life sciences companies held strong US trademark portfolios.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
Accord’s generic hopes dashed in cyanide antidote ruling
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
Novo’s semaglutide protection weakens after European ruling
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.
Pharma
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
8 October 2026   Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.


Editor's picks

Boston Scientific expands dispute with J&J unit over cardiac-access technology
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026

Editor's picks

MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Haynes Boone expands in California with new office
Accord’s generic hopes dashed in cyanide antidote ruling
Novo’s semaglutide protection weakens after European ruling
UK to clamp down on non-compete clauses and long notice periods
Boston Scientific expands dispute with J&J unit over cardiac-access technology
Brazilian firm appoints patent strategist to lead department
AIPPI World Congress: ‘Diversity need not be an obstacle to unity’
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise